Design, synthesis, and evaluation of triazolo[1,5-a]pyridines as novel and potent α‑glucosidase inhibitors.

Journal: Scientific reports
Published Date:

Abstract

α-Glucosidase is a key enzyme responsible for controlling the blood glucose, making a pivotal target in the treatment of type 2 diabetes mellitus. Present work introducestriazolo[1,5-a]pyridine as a novel, potent scaffold for α-glucosidase inhibition. A diverse scope of targeted compounds was prepared through an efficient, straightforward synthetic protocol. A series of compounds (15a-15v) were synthesized using a simple and efficient protocol, all showing notable inhibitory activity. Among them, compound 15j exhibited the best inhibition potency (IC₅₀ = 6.60 ± 0.09 µM), acting as a competitive and selective α-glucosidase inhibitor with no effect on α-amylase. Moreover, comprehensive computational studies were performed to validate the in vitro results and provide insight into compounds' binding interactions within the α-glucosidase's active site. The machine learning model, trained with the Estate fingerprint, achieved an AUC score of 0.65, demonstrating its utility in predicting α-glucosidase inhibition. Random Forest was identified as the most suitable model, and the dataset with the highest R² value was selected for further feature selection and model improvement. Molecular docking studies demonstrated that compound 15j had a strong binding affinity toward α-glucosidase, with a docking score of - 10.04 kcal/mol, and formed several remarkable interactions, particularly three key hydrogen bonds with TYR158, GLN353, and GLU411, contributing to its high inhibitory efficacy. The results of the molecular dynamics simulation demonstrated that the 15j-α-glucosidase complex exhibits high stability and effectively maintains its binding without causing significant structural changes in the enzyme, confirming the stable interaction and selective inhibition of this compound at the enzyme's active site.

Authors

  • Fariba Peytam
    Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Parham Foroumadi
    Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Hayrettin Ozan Gulcan
    Faculty of Pharmacy, Eastern Mediterranean University, via Mersin 10, Famagusta, TRNC, Turkey.
  • Maryam Norouzbahari
    Faculty of Pharmacy, Final International University, Kyrenia via Mersin 10 Turkey, Catalkoy, TRNC, Turkey.
  • Somayeh Mojtabavi
    Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammad Ali Faramarzi
    Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Fahimeh Ghasemi
    Department of Bioelectric and Biomedical engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Hezar-Jerib Ave, Isfahan, 81746 73461, IR, Iran.
  • Mohammadreza Torabi
    Department of Bioinformatics and Systems Biology, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Iran.
  • Behnaz Bameri
    Department of Toxicology and Pharmacology, Faculty of Pharmacy and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
  • Maliheh Barazandeh Tehrani
    Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Loghman Firoozpour
    Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. firoozpour@gmail.com.
  • Alireza Foroumadi
    Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.